Suppr超能文献

克罗恩病和溃疡性结肠炎患者肠道并发症及肠外表现的终生风险增加。

Increased Lifetime Risk of Intestinal Complications and Extraintestinal Manifestations in Crohn's Disease and Ulcerative Colitis.

作者信息

Lichtenstein Gary R, Shahabi Ahva, Seabury Seth A, Lakdawalla Darius N, Espinosa Oliver Díaz, Green Sarah, Brauer Michelle, Baldassano Robert N

机构信息

Department of Medicine, Center for Inflammatory Bowel Disease, Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

Health Policy and Economics, Precision Health Economics, Los Angeles, California.

出版信息

Gastroenterol Hepatol (N Y). 2022 Jan;18(1):32-43.

Abstract

Patients with Crohn's disease (CD) or ulcerative colitis (UC) have high morbidity rates owing to debilitating intestinal complications and extraintestinal manifestations (EIMs). We retrospectively identified patients in the Truven MarketScan databases with an incident CD or UC diagnosis from January 2008 to September 2015 to quantify the incremental lifetime risk of experiencing an intestinal complication or EIM after CD or UC diagnosis. Seven intestinal complications and 13 categories of EIMs by site were identified, and lifetime risk of experiencing an intestinal complication or EIM from age at CD or UC diagnosis to end of life was estimated using parametric models. Results were compared with controls' propensity score matched by age, sex, health plan, and pre-index Charlson Comorbidity Index. The CD or UC incremental risk was calculated using the difference in rates between CD or UC patients and matched controls. A total of 34,692 CD patients and 48,196 UC patients with 1:1 matched controls were included. CD and UC patients had an increased lifetime risk of intestinal complications, which varied across ages, inflammatory bowel disease (IBD) types, and categories of intestinal complications and EIMs. CD and UC patients aged 0 to 11 years had the highest incremental lifetime risk for all 7 intestinal complications and the majority of EIMs, with blood EIMs associated with the highest incremental risk (CD: 32%; UC: 21%). CD and UC patients of all ages have a higher lifetime risk of experiencing intestinal complications and EIMs than patients without CD or UC. When evaluating the burden of disease on patients with IBD, it is important to include the burden of these intestinal complications and EIMs in the assessment.

摘要

克罗恩病(CD)或溃疡性结肠炎(UC)患者由于肠道功能衰弱并发症及肠外表现(EIMs)而具有较高的发病率。我们回顾性地在Truven MarketScan数据库中识别出2008年1月至2015年9月期间首次诊断为CD或UC的患者,以量化CD或UC诊断后发生肠道并发症或EIMs的终生增量风险。识别出7种肠道并发症以及按部位划分的13类EIMs,并使用参数模型估计从CD或UC诊断时的年龄到生命结束时发生肠道并发症或EIMs的终生风险。将结果与按年龄、性别、健康计划和指数前查尔森合并症指数匹配的对照组倾向得分进行比较。使用CD或UC患者与匹配对照组之间的发病率差异计算CD或UC的增量风险。共纳入34,692例CD患者和48,196例UC患者以及1:1匹配的对照组。CD和UC患者发生肠道并发症的终生风险增加,这在不同年龄、炎症性肠病(IBD)类型、肠道并发症和EIMs类别中有所不同。0至11岁的CD和UC患者在所有7种肠道并发症和大多数EIMs方面终生增量风险最高,血液EIMs的增量风险最高(CD:32%;UC:21%)。所有年龄段的CD和UC患者发生肠道并发症和EIMs的终生风险均高于无CD或UC的患者。在评估IBD患者的疾病负担时,在评估中纳入这些肠道并发症和EIMs的负担很重要。

相似文献

2
Extraintestinal Manifestations and Other Comorbidities in Ulcerative Colitis and Crohn Disease: A Danish Nationwide Registry Study 2003-2016.
Crohns Colitis 360. 2020 Aug 25;2(3):otaa070. doi: 10.1093/crocol/otaa070. eCollection 2020 Jul.
3
Temporal Relationship of Extraintestinal Manifestations in Inflammatory Bowel Disease.
J Clin Med. 2021 Dec 20;10(24):5984. doi: 10.3390/jcm10245984.
4
The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients.
United European Gastroenterol J. 2021 Sep;9(7):773-780. doi: 10.1002/ueg2.12125. Epub 2021 Aug 25.
5
Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: Frequency and relation with disease phenotype.
Indian J Gastroenterol. 2015 Jan;34(1):43-50. doi: 10.1007/s12664-015-0538-7. Epub 2015 Feb 7.
6
Smoking increases the risk of extraintestinal manifestations in Crohn's disease.
World J Gastroenterol. 2014 Sep 14;20(34):12269-76. doi: 10.3748/wjg.v20.i34.12269.
8
Extraintestinal manifestations in a large series of Italian inflammatory bowel disease patients.
World J Gastroenterol. 2014 Dec 14;20(46):17463-7. doi: 10.3748/wjg.v20.i46.17463.
9
Prevalence and characteristics of ophthalmological extra-intestinal manifestations in Chinese patients with inflammatory bowel disease.
Int J Ophthalmol. 2016 Oct 18;9(10):1476-1479. doi: 10.18240/ijo.2016.10.18. eCollection 2016.
10
Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease.
Scand J Gastroenterol. 2016 Jul;51(7):848-54. doi: 10.3109/00365521.2016.1140807. Epub 2016 Feb 16.

引用本文的文献

5
Prevalence, incidence, and treatment patterns of fistulizing Crohn disease: A US population-based cohort study.
J Manag Care Spec Pharm. 2024 May;30(5):420-429. doi: 10.18553/jmcp.2024.30.5.420.
7
PVA enema ameliorates DSS-induced acute colitis in mice.
BMC Gastroenterol. 2023 Oct 30;23(1):368. doi: 10.1186/s12876-023-03005-w.
9
Prevalence of skin lesions in a sample of Brazilian patients with inflammatory bowel disease.
Rev Assoc Med Bras (1992). 2023 Aug 14;69(8):e20230165. doi: 10.1590/1806-9282.20230165. eCollection 2023.

本文引用的文献

1
Emerging treatment options for extraintestinal manifestations in IBD.
Gut. 2021 Apr;70(4):796-802. doi: 10.1136/gutjnl-2020-322129. Epub 2020 Aug 26.
2
Lifetime Economic Burden of Crohn's Disease and Ulcerative Colitis by Age at Diagnosis.
Clin Gastroenterol Hepatol. 2020 Apr;18(4):889-897.e10. doi: 10.1016/j.cgh.2019.07.022. Epub 2019 Jul 18.
3
The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy.
J Crohns Colitis. 2019 Apr 26;13(5):541-554. doi: 10.1093/ecco-jcc/jjy191.
4
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Inflamm Bowel Dis. 2018 Aug 16;24(9):1876-1882. doi: 10.1093/ibd/izy065.
5
United States Life Tables, 2012.
Natl Vital Stat Rep. 2016 Nov;65(8):1-65.
7
Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported.
Dig Dis Sci. 2016 Sep;61(9):2619-26. doi: 10.1007/s10620-016-4195-1. Epub 2016 May 19.
8
Inflammatory Bowel Disease in Children and Adolescents.
JAMA Pediatr. 2015 Nov;169(11):1053-60. doi: 10.1001/jamapediatrics.2015.1982.
9
Inflammatory bowel disease cause-specific mortality: a primer for clinicians.
Inflamm Bowel Dis. 2014 Dec;20(12):2483-92. doi: 10.1097/MIB.0000000000000173.
10
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Clin Gastroenterol Hepatol. 2015 May;13(5):847-58.e4; quiz e48-50. doi: 10.1016/j.cgh.2014.05.015. Epub 2014 May 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验